{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:54:55Z","timestamp":1791590095746,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.semarthrit.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T17:21:23Z","timestamp":1457544083000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients"],"prefix":"10.1016","volume":"46","author":[{"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Santos-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Rubio-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cordero-Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Gallego-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Veroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix Francisco","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Atanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loricera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Gonz\u00e1lez-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Palmou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.03.002_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0889-857X(05)70044-2","article-title":"Psoriatic arthritis","volume":"24","author":"Gladman","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0889-857X(05)70042-9","article-title":"Bowel inflammation and the spondyloarthropathies","volume":"24","author":"De Keyser","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib3","series-title":"Educational review manual in rheumatology","first-page":"1","article-title":"Spondyloarthropathies","author":"Gladman","year":"2002"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.bor.0000167753.01168.bd","article-title":"Classification of the spondyloarthropathies","volume":"17","author":"Healy","year":"2005","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl. 55","key":"10.1016\/j.semarthrit.2016.03.002_bib5","first-page":"S56","article-title":"Extra-articular manifestations","volume":"27","author":"Mielants","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-015-2960-8","article-title":"Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease","volume":"34","author":"Rosenbaum","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib11","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib12","first-page":"81","article-title":"Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine","volume":"60","author":"Dougados","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/eye.2008.198","article-title":"Methotrexate: an option for preventing the recurrence of acute anterior uveitis","volume":"23","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.survophthal.2005.04.003","article-title":"Acute anterior uveitis and HLA-B27","volume":"50","author":"Chang","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0161-6420(98)99033-9","article-title":"Outcomes in anterior uveitis associated with the HLAB27 haplotype","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib16","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib19","first-page":"S10","article-title":"Observed incidence rates of uveitis over 96 weeks of certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"66","author":"Rosenbaum","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"11","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib22","first-page":"159","article-title":"Golimumab: a novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis","volume":"4","author":"Kay","year":"2010","journal-title":"Core Evid"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor \u03b1 inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ceo.12207","article-title":"Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series","volume":"42","author":"Faez","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib26","first-page":"864","article-title":"Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib27","doi-asserted-by":"crossref","first-page":"717598","DOI":"10.1155\/2014\/717598","article-title":"Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience","volume":"2014","author":"Cordero-Coma","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib29","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib30","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ophtha.2011.05.019","article-title":"Golimumab for uveitis","volume":"118","author":"Cordero-Coma","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","article-title":"Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"William","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib34","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semarthrit.2016.03.002_bib35","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"issue":"4 Suppl. 84","key":"10.1016\/j.semarthrit.2016.03.002_bib36","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib37","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2032s disease: a 1-year follow-up study of 124 patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273940801899822","article-title":"International Uveitis Study Group (IUSG) clinical classification of uveitis","volume":"16","author":"Deschenes","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib39","first-page":"509","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"The standardization of uveitis nomenclature (SUN) working group","year":"2005","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib41","first-page":"484","article-title":"An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group","volume":"31","author":"Sampaio-Barros","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02238938","article-title":"Polymorphism of the LMP2 gene and disease phenotype in ankylosing spondylitis: no association with disease severity","volume":"16","author":"Maksymowych","year":"1997","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","article-title":"Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis","volume":"23","author":"Feldtkeller","year":"2003","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard.2005.041103","article-title":"Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis","volume":"65","author":"Jaakkola","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/art.1780400221","article-title":"Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses","volume":"40","author":"Ba\u00f1ares","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib46","first-page":"792","article-title":"Characterization of uveitis associated with spondyloarthritis","volume":"16","author":"Rosenbaum","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib47","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-006-0203-7","article-title":"Characterization and outcome of uveitis in 350 patients with spondyloarthropathies","volume":"26","author":"Sampaio-Barros","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2004.08.053","article-title":"Psoriatic uveitis: a distinct clinical entity?","volume":"139","author":"Durrani","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/S0365-05962012000600009","article-title":"Psoriasis and uveitis: a literature review","volume":"87","author":"Fraga","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/XXII.suppl_2.144","article-title":"Acute anterior uveitis (AAU) and HLA-B27","volume":"22","author":"Rothova","year":"1983","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0002-9394(14)70533-1","article-title":"Clinical features and associated systemic diseases of HLA-B27 uveitis","volume":"121","author":"Tay-Kearney","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib52","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"4","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib54","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib55","first-page":"21","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et\u2032s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib57","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis","volume":"33","author":"Santos Lacomba","year":"2001","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00002281-200107000-00001","article-title":"New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy","volume":"13","author":"Braun","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"6","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib61","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14712598.2013.839653","article-title":"Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis\u2014a five-year update","volume":"13","author":"Poddubnyy","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib62","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib63","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor \u03b1 inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.03.002_bib66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T10:55:40Z","timestamp":1567680940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0049017216000925"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}